Novel paradigm enables accurate monthly gestational screening to prevent congenital toxoplasmosis and more
PLOS Neglected Tropical Diseases · 2024
DOI: 10.1371/journal.pntd.0011335 ↗Kurz gefasst
Klinische Studie in der Zeitschrift PLOS Neglected Tropical Diseases, 2024. Verfasst von Ying Zhou und 35 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Ophthalmology and Visual Science, The University of Chicago, Chicago, Illinois, United States of America. Hauptthemen laut MEDLINE: Toxoplasmosis, Congenital. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCIRD CDC HHS, NIAID NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Background
Congenital toxoplasmosis is a treatable, preventable disease, but untreated causes death, prematurity, loss of sight, cognition and motor function, and substantial costs worldwide.
Objectives
We asked whether high performance of an Immunochromatographic-test (ICT) could enable accurate, rapid diagnosis/treatment, establishing new, improved care-paradigms at point-of-care and clinical laboratory.
Methods
Data were obtained in 12 studies/analyses addressing: 1-feasibility/efficacy; 2-false-positives; 3-acceptability; 4-pink/black-line/all studies; 5-time/cost; 6-Quick-Information/Limit-of-detection; 7, 8-acute;-chronic; 9-epidemiology; 10-ADBio; 11,12-Commentary/Cases/Chronology.
Findings
ICT was compared with gold-standard or predicate-tests. Overall, ICT performance for 1093 blood/4967 sera was 99.2%/97.5% sensitive and 99.0%/99.7% specific. However, in clinical trial, FDA-cleared-predicate tests initially caused practical, costly problems due to false-positive-IgM results. For 58 persons, 3/43 seronegative and 2/15 chronically infected persons had false positive IgM predicate tests. This caused substantial anxiety, concerns, and required costly, delayed confirmation in reference centers. Absence of false positive ICT results contributes to solutions: Lyon and Paris France and USA Reference laboratories frequently receive sera with erroneously positive local laboratory IgM results impeding patient care. Therefore, thirty-two such sera referred to Lyon’s Reference laboratory were ICT-tested. We collated these with other earlier/ongoing results: 132 of 137 USA or French persons had false-positive local laboratory IgM results identified correctly as negative by ICT. Five false positive ICT results in Tunisia and Marseille, France, emphasize need to confirm positive ICT results with Sabin-Feldman-Dye-test or western blot. Separate studies demonstrated high performance in detecting acute infections, meeting FDA, CLIA, WHO REASSURED, CEMark criteria and patient and physician satisfaction with monthly-gestational-ICT-screening. Conclusions/significance This novel paradigm using ICT identifies likely false positives or raises suspicion that a result is truly positive, rapidly needing prompt follow up and treatment. Thus, ICT enables well-accepted gestational screening programs that facilitate rapid treatment saving lives, sight, cognition and motor function. This reduces anxiety, delays, work, and cost at point-of-care and clinical laboratories.
Trial registration
NCT04474132 , https://clinicaltrials.gov/study/NCT04474132 ClinicalTrials.gov
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Ophthalmology and Visual Science, The University of Chicago, Chicago, Illinois, United States of America.
- Department of Obstetrics and Gynecology, The University of Chicago, Chicago, Illinois, United States of America.
- Pritzker School of Medicine, Division of Infectious Diseases, The University of Chicago, Chicago, Illinois, United States of America.
- Chicago Medicine, The University of Chicago, Chicago, Illinois, United States of America.
- Department of Pediatrics, Division of Infectious Diseases, The University of Chicago, Chicago, Illinois, United States of America.
- Department of Medicine, The University of Chicago, Chicago, Illinois, United States of America.
ORCID-Profile: Rima McLeod
Förderung
- NCIRD CDC HHS
- NIAID NIH HHS
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
- Thrasher Research Fund
- the Kiphart Global-Local Health Seed Fund Award
- University of Chicago
Zitieren
APA
Zhou, Y., Leahy, K., Grose, A., Lykins, J., Siddiqui, M., Leong, N., Goodall, P., Withers, S., Ashi, K., Schrantz, S., Tesic, V., Abeleda, A. P., Beavis, K., Clouser, F., Ismail, M., Christmas, M., Piarroux, R., Limonne, D., Chapey, E., …, & McLeod, R. (2024). Novel paradigm enables accurate monthly gestational screening to prevent congenital toxoplasmosis and more. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0011335
Vancouver
Zhou Y, Leahy K, Grose A, Lykins J, Siddiqui M, Leong N, et al. Novel paradigm enables accurate monthly gestational screening to prevent congenital toxoplasmosis and more. PLOS Neglected Tropical Diseases. 2024. doi:10.1371/journal.pntd.0011335
BibTeX
@article{Zhou2024,
author = {Zhou, Ying and Leahy, Karen and Grose, Andrew and Lykins, Joseph and Siddiqui, Maryam and Leong, Nicole and Goodall, Perpetua and Withers, Shawn and Ashi, Kevin and Schrantz, Stephen and Tesic, Vera and Abeleda, Ana Precy and Beavis, Kathleen and Clouser, Fatima and Ismail, Mahmoud and Christmas, Monica and Piarroux, Raphael and Limonne, Denis and Chapey, Emmanuelle and Abraham, Sylvie and Baird, Isabelle and Thibodeau, Juliette and Boyer, Kenneth M and Torres, Elizabeth and Conrey, Shannon and Wang, Kanix and Staat, Mary Allen and Back, Nancy and L'Ollivier, Coralie and Mahinc, Caroline and Flori, Pierre and Gomez-Marin, Jorge and Peyron, Francois and Houzé, Sandrine and Wallon, Martine and McLeod, Rima},
title = {Novel paradigm enables accurate monthly gestational screening to prevent congenital toxoplasmosis and more},
journal = {PLOS Neglected Tropical Diseases},
year = {2024},
doi = {10.1371/journal.pntd.0011335}
}
EUVIMED